Clofarabine for Langerhans in Pedi

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2014 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Carlos Rodriguez-Galindo, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01796405
First received: February 19, 2013
Last updated: July 9, 2014
Last verified: July 2014
  Purpose

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different diseases. It also means that the FDA has not yet approved clofarabine for your disease.

Clofarabine is a chemotherapy drug that has been used in the treatment of leukemia in children and adults. Information from other research studies suggests that this drug may also be effective in patients with LCH.

The purpose of this study is to estimate the response rates of participants with recurrent LCH to clofarabine within each of two strata: a) low-risk participants with disease reactivation, and b) high-risk participants with risk-organ involvement.

Other purposes are to estimate the progression-free survival after clofarabine treatment, estimate survival of participants with refractory multi-system LCH with risk organ involvement treated with clofarabine and to describe toxicities of clofarabine in participants with LCH.


Condition Intervention Phase
Langerhans Cell Histiocytosis
Drug: Clofarabine
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis

Resource links provided by NLM:


Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Estimated Response Rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To estimate the response rate of participants with recurrent LCH to clofarabine within each of two strata: a) low-risk participants with disease reactivation; and b) high-risk participants with risk-organ involvement that is refractory to standard treatment.


Secondary Outcome Measures:
  • Estimated of Progression Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To estimate the progression-free survival after clofarabine treatment

  • Estimated survival with risk organ involvement [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To estimate survival of participants with refractory multi-system LCH with risk organ involvement treated with clofarabine

  • Chemotherapy feasibility [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine if clofarabine therapy can be delivered as planned ('chemotherapy feasibility'), and to describe toxicities of clofarabine in participants with LCH.


Estimated Enrollment: 85
Study Start Date: October 2014
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low-Risk
Multifocal or Low-Risk Multi System Clofarabine, Low Dose, Two Cycles
Drug: Clofarabine
Experimental: High-Risk
High-risk Multi System Clofarabine, Standard Dose, Two Cycles
Drug: Clofarabine

Detailed Description:

If you are willing to participate in this research study you will be asked to undergo some screening test or procedure to find out if you are eligible. Many of these tests and procedures are likely to be part of regular care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. These tests and procedures include the following: a medical history, performance status, blood tests, assessment of disease and pregnancy test. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in this research study. After confirming eligibility you will also have a bone marrow test, electrocardiogram and urinalysis.

You will receive a maximum of 6 cycles of study treatment. Each treatment cycle will last approximately 4 weeks. In each cycle, you will receive the study drug clofarabine daily on the first 5 days (days 1 to 5) and rest for the remaining days. Clofarabine will be administered into the vein (IV) over two hours in the clinic or in the hospital. If you have high-risk disease, the dose of clofarabine will be higher during the first two cycles.

Before the start of each cycle, and at the end of your therapy, you will have a physical exam and you will be asked questions about your general health and specific questions about any problems that you are having and any medications you are taking. You will also have blood and urine tests done to monitor organ functions. You will also undergo an assessment of your disease by x-ray, CT scan, MRI or PET or bone scans, which wil be performed every two cycles and at the end of study treatment.

After the final dose of the study drug there will be a follow up period. Once every three months for the first year, twice yearly for the second and third years, and then annually, you will have a physical exam and be asked questions about your general health. You will also have blood and urine tests performed.

Twice yearly for the first three years, x-ray, CT scan, MRI, PET, and/or bone scans will be repeated if your doctor feels they are necessary.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have failed first line treatment with prednisone and vinblastine
  • Clinical evidence of involvement of hematopoietic system, liver or spleen
  • Have failed salvage treatment with cladribine/cytarabine or are not considered to be eligible for such treatment
  • Willing to use effective contraception during study and for six months after study treatment
  • Adequate marrow and organ function

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Have received chemotherapy or radiotherapy within 2 weeks of study entry
  • Have not recovered from adverse events due to previously administered agents
  • Receiving other study agents
  • Taking drugs with known renal toxicity
  • Use of alternative medicine during study treatment
  • Uncontrolled intercurrent illness
  • History of a different malignancy except if disease-free for at least five years or within five years for cervical cancer in situ and basal and squamous cell carcinoma of the skin
  • Known to be HIV positive on antiretroviral therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01796405

Contacts
Contact: Carlos Rodriguez-Galindo, MD 6176324580 crodriguez-galindo@partners.org

Locations
United States, Massachusetts
Boston Children's Hospital Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Carlos Rodriguez-Galindo, MD    617-632-4580    crodriguez-galindo@partners.org   
Principal Investigator: Carlos Rodriguez-Galindo, MD         
Dana-Farber Cancer Institute Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Eric Jacobsen, MD    617-632-6635    ejacobsen@partners.org   
Principal Investigator: Eric Jacobsen, MD         
Brigham and Women's Hospital Not yet recruiting
Boston, Massachusetts, United States, 02215
Contact: Eric Jacobsen, MD    617-632-6633    ejacobsen@partners.org   
Principal Investigator: Eric Jacbosen, MD         
Sponsors and Collaborators
Dana-Farber Cancer Institute
  More Information

No publications provided

Responsible Party: Carlos Rodriguez-Galindo, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT01796405     History of Changes
Other Study ID Numbers: 12-050
Study First Received: February 19, 2013
Last Updated: July 9, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Histiocytosis
Histiocytosis, Langerhans-Cell
Lymphatic Diseases
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Clofarabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 19, 2014